Bob Kamen is an entrepreneur-in-residence at Third Rock Ventures with more than 30 years of experience in the pharmaceutical and biotechnology industries. He served as president of Abbott Bioresearch Center, where he oversaw the discovery and production of Humira®, the first fully human antibody to achieve marketing approval in the U.S. and Europe, and was a member of the Abbott Pharmaceuticals Executive Management Committee. Dr. Kamen also served as the president of BASF Bioresearch Corp. until it was acquired by Abbott Laboratories in 2001. Earlier in his career, Dr. Kamen led discovery at Genetics Institute, Inc. In 2005, Dr. Kamen co-founded BioAssets Development Corporation, a biotherapeutics company focusing on spinal diseases, acquired by Cephalon in 2010. Dr. Kamen is a director of Harbour Antibodies BV, Lycera Corp. and Opsonic Therapeutics, and an advisor to other biopharmaceutical companies. Dr. Kamen holds an undergraduate degree in biophysics from Amherst College and a PhD in biochemistry and molecular biology from Harvard University.

biochemistry and molecular biology